Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]
Discontinued
Reference number: GID-TA11093
Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer have been revised. It is anticipated that the appraisal will begin in early-February 2024 when we will write to you about how you can get involved.